BRIACELL THERAPEUTICS CORP (BCTX) Stock News

NASDAQ:BCTX - CA1079302081 - Common Stock

7.97 USD

+0.04 (+0.5%)

Last: 9/9/2025, 8:00:00 PM

7.97 USD

0 (0%)

Pre-Market: 9/10/2025, 5:23:09 AM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

BCTX Latest News, Press Relases and Analysis

All

Press Releases

15 days ago - By: BriaCell Therapeutics Corp. - Mentions: BCT.CA

BriaCell’s Bria-OTS+™ Mechanism of Action Validated in Highly Rated Peer Reviewed Cancer Journal

16 days ago - By: BriaCell Therapeutics Corp. - Mentions: BCT.CA

BriaCell Awarded $2 Million NCI Grant to Advance Bria-PROS+™ in Prostate Cancer

20 days ago - By: BriaCell Therapeutics Corp. - Mentions: BCT.CA

BriaCell Announces Proposed Effective Date of Share Consolidation

a month ago - By: BriaCell Therapeutics Corp. - Mentions: BCT.CA

BriaCell Selected for MSK’s 2025 Therapeutics Accelerator Program for Bria-OTS+™ for Cancer

a month ago - By: BriaCell Therapeutics Corp. - Mentions: BCT.CA

BriaCell Announces Proposed Effective Date of Share Consolidation

a month ago - By: BriaCell Therapeutics Corp. - Mentions: BCT.CA

BriaCell Adds UCLA Health as Key Site in Pivotal Phase 3 Breast Cancer Study

a month ago - By: BriaCell Therapeutics Corp. - Mentions: BCT.CA

BriaCell Awarded New Zealand Patent for its Whole Cell Technology

a month ago - By: BriaCell Therapeutics Corp.; BriaPro Therapeutics Corp. - Mentions: BCT.CA

BriaCell’s Subsidiary, BriaPro, Files Patent Application for Immuno-Oncology Platform with Novel Multitargeting Agents

2 months ago - By: BriaCell Therapeutics Corp. - Mentions: BCT.CA

BriaCell Announces Two Clinical Data Poster Presentations at ESMO 2025

2 months ago - By: BriaCell Therapeutics Corp. - Mentions: BCT.CA

BriaCell Therapeutics Announces Closing of $15 million Public Offering

2 months ago - By: BriaCell Therapeutics Corp. - Mentions: BCT.CA

BriaCell Therapeutics Announces Pricing of $15 million Public Offering

2 months ago - By: BriaCell Therapeutics Corp. - Mentions: BCT.CA

BriaCell Adds Mayo Clinic to Phase 3 Study in Metastatic Breast Cancer

2 months ago - By: BriaCell Therapeutics Corp. - Mentions: BCT.CA

BriaCell’s Bria-IMT™ Demonstrates Survival Advantage over Trodelvy® and Control Group in Metastatic Breast Cancer

2 months ago - By: BriaCell Therapeutics Corp. - Mentions: BCT.CA

BriaCell Reports Complete and Sustained Resolution of Brain Metastasis and Sustained Regression of Orbital Metastasis in “Eye-Bulging” Breast Cancer Patient

2 months ago - By: BriaCell Therapeutics Corp. - Mentions: BCT.CA

BriaCell Patient Achieves Sustained Complete Resolution of Lung Metastasis in Bria-OTS™ Metastatic Breast Cancer Study

2 months ago - By: BriaCell Therapeutics Corp. - Mentions: BCT.CA

BriaCell Phase 2 Survival Achievement: 52% of Patients Surpass One-Year Milestone in Metastatic Breast Cancer

2 months ago - By: BriaCell Therapeutics Corp. - Mentions: BCT.CA

BriaCell Highlights Additional Phase 3 Clinical Sites Including Los Angeles Cancer Network and Smilow Cancer Hospital at Yale New Haven

3 months ago - By: BriaCell Therapeutics Corp. - Mentions: BCT.CA

BriaCell Announces Positive Recommendation from Data Safety Monitoring Board for Pivotal Phase 3 Study in Metastatic Breast Cancer

3 months ago - By: BriaCell Therapeutics Corp. - Mentions: BCT.CA

BriaCell Announces Virtual Investor Presentations on Thursday, June 12 and Thursday, June 26

3 months ago - By: BriaCell Therapeutics Corp. - Mentions: BCT.CA

BriaCell Reports Robust Overall Survival and Clinical Benefit Data at ASCO 2025

4 months ago - By: BriaCell Therapeutics Corp. - Mentions: BCT.CA

BriaCell Bria-OTS™ Phase 1/2 Study Clears Safety Evaluation; Doses First Patient in Combination with Checkpoint Inhibitor

4 months ago - By: BriaCell Therapeutics Corp. - Mentions: BCT.CA

BriaCell Abstracts Showcase Positive Survival and Clinical Benefit Data at ASCO 2025

4 months ago - By: BriaCell Therapeutics Corp. - Mentions: BCT.CA

BriaCell CEO Letter to Shareholders

4 months ago - By: BriaCell Therapeutics Corp. - Mentions: BCT.CA

BriaCell Reports “Late-Breaker” Phase 3 Data at AACR 2025: Positive Tolerability Profile and Potential Response Biomarkers Identified

4 months ago - By: BriaCell Therapeutics Corp. - Mentions: BCT.CA

BriaCell Therapeutics Announces Closing of $13.8 million Public Offering

5 months ago - By: BriaCell Therapeutics Corp. - Mentions: BCT.CA

BriaCell Presents Benchmark Beating Survival and Clinical Benefit at AACR 2025; Advancements in Next Generation Bria-OTS+™ Development

5 months ago - By: Benzinga - Mentions: COUR JZXN CEP CPOP ...

Why Coursera Shares Are Trading Higher By Over 7%; Here Are 20 Stocks Moving Premarket

5 months ago - By: BriaCell Therapeutics Corp. - Mentions: BCT.CA

BriaCell Therapeutics Announces Pricing of $13.8 million Public Offering